Contact CVRx

BeAT–HF trial results

Barostim BAT achieves significant and meaningful improvements in heart failure symptoms

+60
Meters
greater 6MHW results with BAT
6MHW Data
34%
Improved
more improved at least 1 NYHA class at 6 months (p<0.001)
NYHA Class Data
-14
Points
improvement in QOL with BAT
Heart Failure QoL Data

Significant reduction in NT-proBNP and collection of morbidity and mortality data

25%
NT-proBNP
reduction in NT-proBNP with Barostim
NT-proBNP Data

1. Zile MR, Abraham WT, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction, J Am Coll Cardiol 2020; 76:1-13

Safe procedures and a potential reduction in serious cardiovascular events

97%
MANCE-free rate in BAT arm
51%
*Potential reduction in serious cardiovascular-related hospitalization events with BAT

* https://www.cvrx.com/newsroom/see-the-6-month-data-from-the-beat-heart-failure-study-presented-on-27-may-2019-at-esc-hf/